Innovation Pharmaceuticals (IPIX) 10-Q2015 Q1 Quarterly report

Filed: 10 Nov 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: Alabama, Alexander, Allergy, Angel, anticancer, apoptotic, array, assist, asthma, Attenuating, back, baseline, Beecham, BioCryst, biomarker, Birmingham, book, breakthrough, Candida, certified, Chase, Chemical, chemotherapy, choose, COPD, core, counsel, crucial, Daily, decrease, deducted, defense, degradation, delivery, depict, diabetic, display, distinction, Diversity, dollar, duration, employed, encoded, exhibiting, experienced, experiencing, eye, FCCDC, foot, footnote, fourth, Fox, fuel, gene, Genome, Glaxo, Guardian, HDAC, HDP, histonedeacetylase, HIV, host, influenza, intestinal, Joe, Klebsiella, led, lesion, Lymphoma, MDAnderson, mechanism, medicine, migraine, Mississippi, mutant, Myeloma, NIAID, package, peripheral, pharmacovigilance, platform, pneumoniae, potent, progressing, proliferation, proprietorship, protein, protocol, published, Radiotherapy, recognition, refrigerated, remeasurement, removal, removing, representing, rescue, retrospective, role, room, SAE, SBIR, served, serving, signal, SmithKline, stable, statistically, stored, sublease, supersede, suppressor, temperature, tightly, today, Topic, toxicity, trained, type, unchanged, unused, Variable, Vice, viral, Wellcome, wild, William

Removed: AACR, abandoned, accurate, activate, adjustment, American, amortizable, antitumor, appointed, augment, authoritative, BIDMC, blinded, bring, Canada, carcinoma, carrying, caspase, classified, cleavage, collect, comprised, consistently, create, cumulative, Dana, dated, deficiency, demonstrating, detected, devote, discover, driven, emerged, enacted, encouraging, engineering, enhance, Excellence, excessive, exploit, Farber, forward, function, functioning, gained, harm, hospital, hypertension, immune, impairment, implementation, inability, inducing, induction, initiate, initiated, insight, institution, investigate, likelihood, liquid, lost, maintained, measuring, melanoma, minimal, mitochondria, mitochondrial, modulation, monoubiquitination, move, MRSA, multikinase, multinational, MW, NOL, nuclear, occurred, open, ordinary, original, PARP, path, point, predictor, prevented, program, provision, QTDP, Qualifying, realize, realized, reconciliation, recoverable, recovered, recur, Reddy, redeemed, reduced, reformulating, relate, remediated, remediation, renal, Russia, School, segment, segregate, segregation, sensitive, separate, short, SPORE, stabilizing, synergistic, synthesized, taxable, teaching, test, tested, Therapeutic, therapy, translocation, TUNEL, Ukraine, ultimate, undiscounted, unrecognized, utilization, vascularity, VEGFR, viable, vital, xenograft

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IPIX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Cellceutix Corporation, a Nevada corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report on Form 10-Q for the three months ended September 30, 2014 of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Cellceutix Corporation and will be retained by Cellceutix Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: November 10, 2014		/s/ Krishna Menon
		Krishna Menon
		President and Director